About DSIP Rx
A named substance can remain a long way from a useful medicine. DSIP's distance interests me.
Why this candidate?
DSIP acquired a remarkably persuasive name: delta sleep-inducing peptide. It also acquired Emideltide, an International Nonproprietary Name. Yet the review of its sleep biology still leaves the receptor, gene and precursor unresolved. That official-sounding identity sits awkwardly with unfinished science. The mismatch interests me.
The small human insomnia study convinced me the candidate warranted attention. Longer sleep with fewer interruptions and no reported daytime sedation is an appealing result. The slight arousal before the sleep effect, the small sample and the later inconsistencies made the story much less straightforward than I expected.
I trust a peculiar experiment more readily than a broad reputation. The rat stroke result, with better movement and no significant reduction in infarct volume, is exactly the kind of complication that makes this subject worth following. It opens a specific question while resisting a tidy therapeutic claim.
DSIP Rx and medical advice
DSIP Rx is a publication. I'm no physician. The Rx in its name asks how close this peptide came to medicine. This website cannot issue a prescription, accept a product order, send a shipment or arrange an appointment.
Nothing here provides medical advice or a judgment about an individual's treatment. A useful discussion of a candidate can still leave its suitability for any particular person completely unanswered. That decision requires a qualified professional who knows the person's health.
The interest, for me, is in the published experiments: how a sleep candidate gained its reputation, which parts survived testing and which parts still wait for an adequate human trial. DSIP remains an unapproved research chemical. A formal name has carried it only so far.